Physician profile
Thomas Robert Kaye
NPI 1861479552
$819.65
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $25.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.60 | 2019-2020 | |
| Novo Nordisk INC | $111.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.79 | 2019 | |
| Amgen INC. | $61.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.94 | 2019 | |
| Indivior INC. | $33.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.90 | 2019 | |
| Ironshore Pharmaceuticals INC. | $27.48 | 2019 | |
| Amarin Pharma, INC. | $26.11 | 2019 | |
| Allergan, INC. | $25.79 | 2019 | |
| Neurocrine Biosciences, INC. | $18.78 | 2019 | |
| Sanofi Pasteur INC. | $17.69 | 2019 | |
| Antares Pharma, INC. | $14.13 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.74 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.